The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School in Plymouth has reached an important milestone with the news that the full cohort of 493 people with multiple sclerosis (MS) has been recruited to the study. CUPID is a clinical trial which will evaluate whether   more »

The CUPID (Cannabinoid Use in Progressive Inflammatory brain Disease) study at the Peninsula Medical School has reached an important milestone with the news that the full cohort of 493 patients with multiple sclerosis (MS) has been recruited to the   more »

Having an older brother or sister with multiple sclerosis does not protect siblings lower on the birth-order ladder from developing the neurological disease, a Canadian study suggests. A genetic predisposition and other factors - not exposure or lack of exposure to germs from an older sibling - are    more »

The study examined the implications of responsibility and obligation on separation-individuation processes and the appearance of various symptoms of psychological distress in    more »

Every cell contains a tiny clock called a telomere, which shortens each time the cell divides. Short telomeres are linked to a range of human diseases, including HIV, osteoporosis, heart disease and aging. Previous studies show that an enzyme within the cell, called telomerase, keeps immune cells young by   more »

MRI is often used as primary outcome measure in phase II clinical trials in multiple sclerosis (MS). Since persistent T1 hypointense lesions are a surrogate parameter for axonal damage   more »

The pathogenesis of tissue injury outside the white matter (WM) plaques of multiple sclerosis (MS) has not yet been clearly defined. To better understand the pathogenesis of this injury and   more »

The 40-mg version of Teva’s blockbuster multiple sclerosis drug Copaxone did not demonstrate increased efficacy compared with   more »

In recent years, stem cell researchers have become very adept at manipulating the fate of adult stem cells cultured in the lab. Now, researchers at the Salk Institute for Biological Studies achieved the same feat with adult neural stem cells still in place in   more »

This Phase III, multi-center, placebo-controlled, 4-week trial evaluated 322 patients with chronic primary insomnia. Patients were randomized to receive either 20 mg or 50 mg of tasimelteon or placebo over the course of four weeks. The primary endpoint consisted of the evaluation of the immediate and short-term (average of Nights 1 and 8) ability of tasimelteon   more »

Whether a patient has poor health or good health can affect his or her behaviours relating to physicians, taking prescription drugs, sources of health information and trust in health care    more »

Using the Danish Multiple Sclerosis Register, the Danish Hospital Discharge Register, and the Danish Civil Registration System, we estimated RRs for 42 different autoimmune diseases in a population-based cohort of 12,403 MS patients   more »

The results, if borne out in further studies, point to a time when doctors will be able to target specific inflammatory processes in the body and more effectively help MS patients, using available   more »

To investigate factors associated with the risk of secondary progression in relapsing-remitting onset multiple sclerosis (MS).   more »